SI2165702T1 - Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo - Google Patents

Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo

Info

Publication number
SI2165702T1
SI2165702T1 SI200830536T SI200830536T SI2165702T1 SI 2165702 T1 SI2165702 T1 SI 2165702T1 SI 200830536 T SI200830536 T SI 200830536T SI 200830536 T SI200830536 T SI 200830536T SI 2165702 T1 SI2165702 T1 SI 2165702T1
Authority
SI
Slovenia
Prior art keywords
candesartan cilexetil
stable
wet granulation
compositions
readily dissolved
Prior art date
Application number
SI200830536T
Other languages
English (en)
Inventor
Frank Dr Gindullis
Sergio Simoes
Da Silva Alberto Gabriel Leitao
Original Assignee
Helm Ag
Bluepharma Ind Farmaceutica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helm Ag, Bluepharma Ind Farmaceutica S A filed Critical Helm Ag
Publication of SI2165702T1 publication Critical patent/SI2165702T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200830536T 2008-09-17 2008-09-17 Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo SI2165702T1 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08016396A EP2165702B1 (en) 2008-09-17 2008-09-17 Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation

Publications (1)

Publication Number Publication Date
SI2165702T1 true SI2165702T1 (sl) 2012-05-31

Family

ID=40291309

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830536T SI2165702T1 (sl) 2008-09-17 2008-09-17 Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo

Country Status (8)

Country Link
EP (1) EP2165702B1 (sl)
AT (1) ATE533474T1 (sl)
DK (1) DK2165702T3 (sl)
ES (1) ES2377552T3 (sl)
HR (1) HRP20120134T1 (sl)
PL (1) PL2165702T3 (sl)
PT (1) PT2165702E (sl)
SI (1) SI2165702T1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5917844B2 (ja) * 2011-06-24 2016-05-18 日本ケミファ株式会社 カンデサルタンシレキセチル製剤
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
JP6379043B2 (ja) * 2013-01-30 2018-08-22 沢井製薬株式会社 カンデサルタンシレキセチル含有医薬組成物
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
EP3219309A1 (en) * 2016-03-17 2017-09-20 K.H.S. Pharma Holding GmbH Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
JP2018141011A (ja) * 2018-05-24 2018-09-13 日本ケミファ株式会社 カンデサルタン シレキセチル製剤
KR20230000506A (ko) * 2021-06-24 2023-01-03 주식회사 종근당 칸데사르탄, 암로디핀 및 아트로바스타틴을 포함하는 약제학적 복합제제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146683B1 (de) 1981-07-31 1987-11-19 Siemens Aktiengesellschaft Wechselrichter
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
TW284688B (sl) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
CN100350977C (zh) 2001-06-14 2007-11-28 大塚制药株式会社 药物组合物
US20030114497A1 (en) 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
WO2004071494A2 (en) 2003-02-13 2004-08-26 Phares Pharmaceutical Research N.V. Lipophilic compositions
WO2005070398A2 (en) 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
EP1711168A2 (en) 2004-01-23 2006-10-18 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005084648A1 (en) 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
BRPI0606434A2 (pt) 2005-01-06 2009-06-30 Elan Pharma Int Ltd formulações de candesartana nanoparticulada
JP2008528456A (ja) 2005-01-26 2008-07-31 レツク・フアーマシユーテイカルズ・デー・デー 親油性結晶性物質としてカンデサルタンシレキセチルを含む新規な医薬組成物
MX2007012947A (es) 2005-04-18 2008-04-09 Rubicon Res Pvt Ltd Composiciones biomejoradas.
CN101222911A (zh) 2005-07-15 2008-07-16 特瓦制药工业有限公司 新的制粒方法及由此制备的颗粒
WO2007077581A2 (en) 2006-01-02 2007-07-12 Rubicon Research Private Limited Pharmaceutical compositions
WO2008065097A2 (en) * 2006-11-28 2008-06-05 Laboratorios Liconsa, S.A. Stabilized solid pharmaceutical composition of candesartan cilexetil
EP1961412A1 (en) * 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
EP1952806A1 (en) 2007-02-01 2008-08-06 Helm AG Process for the preparation of adsorbates of candesartan
DE602008002371D1 (de) * 2007-03-08 2010-10-14 Teva Pharma Pharmazeutische zusammensetzung mit candesartan-cilexetil
EP1997479A1 (en) 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration

Also Published As

Publication number Publication date
HRP20120134T1 (hr) 2012-03-31
EP2165702A1 (en) 2010-03-24
EP2165702B1 (en) 2011-11-16
ATE533474T1 (de) 2011-12-15
DK2165702T3 (da) 2012-03-05
PT2165702E (pt) 2012-02-07
ES2377552T3 (es) 2012-03-28
PL2165702T3 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
SI2165702T1 (sl) Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2011056985A3 (en) Substituted heterocyclic compounds
WO2008033562A3 (en) Kinase inhibitor compounds
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
WO2010078421A8 (en) Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds
EA201100441A1 (ru) Соединения для коррекции уровня мочевой кислоты и способы их применения
WO2008128049A3 (en) Tetrahydrobiopterin compositions and methods of measuring
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
WO2006113631A3 (en) Bioenhanced compositions
MA32175B1 (fr) Oxadiazoanthracènes pour le traitement du diabète
WO2008039431A3 (en) Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA201170289A1 (ru) Фармацевтические композиции и способы их получения при низкой концентрации примесей
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2007143607A3 (en) Method of treating atrophic vaginitis
WO2010135530A3 (en) Compounds, compositions and methods for modulating uric acid levels
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009091550A3 (en) Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
WO2007113202A8 (en) Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists